[EN] FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS EN TANT QUE MODULATEURS DE RÉCEPTEUR D'OREXINE
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2011050200A1
公开(公告)日:2011-04-28
Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
[EN] DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS<br/>[FR] OCTAHYDROPYRROLO[3,4-C]PYRROLES DISUBSTITUÉS EN TANT QUE MODULATEURS DE RÉCEPTEUR D'OREXINE
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2011050198A1
公开(公告)日:2011-04-28
Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as defined in the specification, or a salt thereof.
申请人:PnH tech (주)피엔에이치테크(120100135796) Corp. No ▼ 131111-0237931BRN ▼129-86-36614
公开号:KR20160080420A
公开(公告)日:2016-07-08
본 발명은 유기전계발광소자에 채용되는 유기발광 화합물에 관한 것으로서, 하기 [화학식 1]로 표시되는 것을 특징으로 하고, 이를 발광층 내의 도판트 화합물 또는 정공수송 화합물로 채용하는 경우 구동전압, 휘도 및 장수명 등의 발광특성이 우수한 유기전계발광소자를 구현할 수 있다. [화학식 1]
FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS
申请人:Branstetter Bryan James
公开号:US20120202783A1
公开(公告)日:2012-08-09
Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.